These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29961559)

  • 1. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Meyer LA; He W; Sun CC; Zhao H; Wright AA; Suidan RS; Dottino J; Alejandro Rauh-Hain J; Lu KH; Giordano SH
    Gynecol Oncol; 2018 Sep; 150(3):451-459. PubMed ID: 29961559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
    JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
    Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
    Meyer LA; Cronin AM; Sun CC; Bixel K; Bookman MA; Cristea MC; Griggs JJ; Levenback CF; Burger RA; Mantia-Smaldone G; Matulonis UA; Niland JC; O'Malley DM; Wright AA
    J Clin Oncol; 2016 Nov; 34(32):3854-3863. PubMed ID: 27601552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
    Chambers LM; Jia X; Rose PG; AlHilli M
    Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
    Wright JD; Huang Y; Melamed A; Albright BB; Hillyer GC; Previs R; Hershman MSDL
    Gynecol Oncol; 2021 Sep; 162(3):599-605. PubMed ID: 34158181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
    Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
    Liu YL; Filippova OT; Zhou Q; Iasonos A; Chi DS; Zivanovic O; Sonoda Y; Gardner GJ; Broach VA; O'Cearbhaill RE; Konner JA; Aghajanian C; Long Roche K; Tew WP
    J Gynecol Oncol; 2020 Jan; 31(1):e17. PubMed ID: 31833259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
    Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
    Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
    Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes and predictive factors in patients ≥70 years old with advanced ovarian cancer.
    Piedimonte S; Bernardini MQ; May T; Cybulska P; Ferguson SE; Laframboise S; Bouchard-Fortier G; Avery L; Hogen L
    J Surg Oncol; 2022 Mar; 125(4):736-746. PubMed ID: 34786711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
    Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
    Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
    Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.